The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
Open accessAbstract
Background and aims: Oral aminosalicylates are well established in the treatment of active mild/moderate ulcerative colitis (UC) when the disease is extensive (that is, beyond the splenic flexure). The majority of clinical symptoms relate to disease activity in the distal part of the colon and therefore this study was designed to investigate if adding a mesalazine enema to oral mesalazine has additional benefit for patients with extensive mild/moderate active UC. Methods: A randomised double blind study was performed in 127 ambulatory patients. All received 4 g/day (twice daily dosing) oral mesalazine for eight weeks. During the initial four weeks, they additionally received an enema at bedtime containing 1 g of mesalazine or placebo. Disease activity was assessed using the ulcerative colitis disease activity index, with clinical and endoscopic signs at four and eight weeks. Results: Remission was obtained in 44% (95% confidence interval (CI) 31%, 58%) of the mesalazine enema group (Me) and in 34% (95% CI 21%, 49%) of the placebo enema group (Pl) at four weeks (p = 0.31) and in 64% (95% CI 50%, 76%) of the Me group versus 43% (95% CI 28%, 58%) of the Pl group at eight weeks (p = 0.03). Improvement was obtained in 89% (95% CI 78%, 96%) of the Me group versus 62% (95% CI 46%, 75%) of the Pl group at four weeks (p = 0.0008) and in 86% (95% CI 75%, 94%) of the Me group versus 68% (95% CI 53%, 81%) of the Pl group at eight weeks (p = 0.026). Conclusion: In patients with extensive mild/moderate active UC, the combination therapy is superior to oral therapy. It is safe, well accepted, and may be regarded as firstline treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Sutherland, L. R., Martin, F., Greer, S., Robinson, M., Greenberger, N., Saibil, F., Martin, T., Sparr, J., Prokipchuk, E., & Borgen, L. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90621-4 · Cited by 677
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 494
(1995) · Gastroenterology · doi:10.1016/0016-5085(95)27940-7 · Cited by 322
Cohen, R. D., Woseth, D. M., Thisted, R. A., & Hanauer, S. B. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01940.x · Cited by 277
Hanauer, S., SCHWARTZ, J., ROBINSON, M. G., Roufail, W. M., Arora, S., Cello, J. P., & Safdi, M. A. (1993) · PubMed · Cited by 266
Medical therapy for ulcerative colitis 2004
Hanauer, S. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.071 · Cited by 156
Pentasa UC Maintenance Study Group, Miner, P. B., Hanauer, S. B., ROBINSON, M. G., Schwartz, J., & Arora, S. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02065413 · Cited by 135
Hanauer, S. B., & (For the U.S. PENTASA Enema Study Group) (1998) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199805000-00001 · Cited by 88
Farup, P. G., Hinterleitner, T. A., Lukáš, M., Hébuterne, X., Rachmilewitz, D., Campieri, M., Meier, R. F., Keller, R., Rathbone, B. J., & Oddsson, E. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200108000-00009 · Cited by 66
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60150-0 · Cited by 2,078
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Kobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
Metadata
- Authors
- Marteau, P., Probert, C. S., Lindgren, S., Gassul, M., Tan, T. G., Dignass, A., Befrits, R., Midhagen, G., Rademaker, J., & Foldager, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-06-10
- Volume
- 54
- Issue
- 7
- Pages
- 960-965
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2112273094
- Cited by
- 362
- References
- 11
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. https://app.cochat.ai/papers/10.1136/gut.2004.060103
- The paper
- Marteau, P., Probert, C. S., Lindgren, S., Gassul, M., Tan, T. G., Dignass, A., Befrits, R., Midhagen, G., Rademaker, J., & Foldager, M. (2005). Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. https://doi.org/10.1136/gut.2004.060103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.